Slovakia intends to take an active part in the development of the pharmaceutical enterprise Nativita. The statement was made by Ambassador Extraordinary and Plenipotentiary of Slovakia to Belarus Jozef Migas who took part in the festivities timed to the opening of a research center of the pharmaceutical company SOOO Nativita in Beshenkovichi, Vitebsk Oblast, BelTA has learned.
The diplomat stressed that the pharmaceutical factory established in Vitebsk Oblast using money and technologies of various countries represents an innovative international project. "If we take a closer look at the current accomplishments, it is likely we will soon sign three documents with Nativita and with the pharmaceutical cluster, which has been established in Vitebsk Oblast and of which Nativita is part. From our side the documents will be signed by a chemical analysis, biomedicine, and biochemistry research institute. The institute intends to take part in the development of new medications for treating serious oncological diseases. The second document will be signed by the Vitebsk State Medical University and one of our university faculties specializing in pharmaceutics and healthcare. The third document will be signed by a Slovakian agency that intends to assist with getting these medications certified. It is impossible to sell medications on the European Union market without it," said Jozef Migas.
The diplomat said: "I am glad we've managed to implement such an innovative project, in which Lithuania and India take part in addition to Belarus and Slovakia. Modern and effective medications made by pooling the experience of various countries will surely benefit our citizens."
The pharmaceutical company Nativita is a factory specializing in making medications to treat malignant tumors as well as a number of autoimmune and serious infectious diseases. The company's products have been entered into the national import substitution program. The company was established in 2012. The investors are Natco Pharma Limited (India), OOO VitVar (Vitebsk, Belarus), AO Vita Pharma (Slovakia), and AB ZIA valda (Lithuania). SOOO Nativita will start working in early 2017. Prior to commissioning the main manufacturing lines the company opened its research center that will focus on cutting-edge R&D and will manage quality of the entire lineup of medications.